Hoth Therapeutics (NASDAQ:HOTH) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Hoth Therapeutics (NASDAQ:HOTH) from a sell rating to a hold rating in a report published on Saturday morning.

Separately, D. Boral Capital reissued a “buy” rating and set a $5.00 target price on shares of Hoth Therapeutics in a report on Monday, August 18th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $4.00.

Hoth Therapeutics Stock Up 13.8%

NASDAQ:HOTH opened at $1.82 on Friday. The firm has a market capitalization of $24.13 million, a price-to-earnings ratio of -1.70 and a beta of 0.67. Hoth Therapeutics has a twelve month low of $0.65 and a twelve month high of $3.80. The stock’s 50 day moving average price is $1.34 and its two-hundred day moving average price is $1.12.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.10. As a group, analysts anticipate that Hoth Therapeutics will post -1.36 earnings per share for the current year.

Institutional Trading of Hoth Therapeutics

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC grew its stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 8.0% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 122,575 shares of the company’s stock after acquiring an additional 9,071 shares during the quarter. Geode Capital Management LLC owned about 0.93% of Hoth Therapeutics worth $143,000 as of its most recent SEC filing. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.